{"id":"W2052076354","doi":"10.1007/s10637-013-9931-1","title":"A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Tolerability; Internal medicine; Sunitinib; Clinical endpoint; Renal cell carcinoma; Progressive disease; Phases of clinical research; Pazopanib; Oncology; Adverse effect; Gastroenterology; Clinical trial; Surgery; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001507827,0.0003893894,0.0007656681,0.0002366775,0.00010199,0.00001696708,0.000179992,0.00005742432,0.0002624988],"category_scores_gemma":[0.0001483402,0.0002092597,0.0001460644,0.0006484302,0.0003111254,0.0001627237,0.00007719239,0.0001914704,0.000006923654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003747107,"about_ca_system_score_gemma":0.001686863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001488482,"about_ca_topic_score_gemma":0.0000867904,"domain_scores_codex":[0.9967691,0.0003011908,0.0009703829,0.0004897315,0.001126997,0.0003425973],"domain_scores_gemma":[0.9977503,0.0002774002,0.0007539676,0.0004532428,0.0004230926,0.0003420377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3413877,0.3645458,0.1791364,0.0009325231,0.002762377,0.0004431131,0.06931653,0.0004708428,0.01802215,0.0002403136,0.004610764,0.01813149],"study_design_scores_gemma":[0.7254254,0.1505848,0.03696376,0.0004824176,0.00142289,0.00002100075,0.002299266,0.0003139247,0.08168406,0.0003199224,0.0001144963,0.0003680738],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897096,0.0001801213,0.000001980197,0.0004139292,0.0001046275,0.009234152,0.0001119121,0.00001396953,0.0002296928],"genre_scores_gemma":[0.9972329,0.000002678239,0.0008259481,0.00007261264,0.00008016168,0.0009115597,0.0001470553,0.00003361978,0.0006935256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3840376,"threshold_uncertainty_score":0.8533363,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03995789522017983,"score_gpt":0.3047918596194014,"score_spread":0.2648339643992216,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}